Study design and population.
HIV infection, hepatocellular carcinoma, HBV infections, liver cirrhosis
VIRUS, HIV INFECTION, LIVER CIRRHOSIS, HEPATOCELLULAR CARCINOMA, HEPATITIS
The details of the study design and eligibility criteria have been previously published (Study designNumber of participants with PK data who were administered GSK3389404 is displayed in parenthesis.All participants were on NAs except one participant.All participants were on NAs except two participants.The participants included in this study were adults aged 18 to 70 years with documented chronic HBV infections for at least 6 months prior to screening. Patients were excluded if they had confirmed or suspected hepatocellular carcinoma within 6 months of randomization, a diagnosis or evidence of liver cirrhosis within 12 months of screening, or a positive test for the hepatitis C/D virus or an HIV infection at screening. The participants in Part 1 were either on or not on a stable NA regimen (The study protocol, any amendments, the informed consent, and other information that required preapproval were reviewed and approved by a national, regional, or investigational center ethics committee or an institutional review board (